The human skeleton is, on every available physiological measurement, considerably more dynamic than the standard cultural framing tends to credit. The bones are not, as the framing implies, fixed structural elements that the body maintains across decades without modification. The bones are, more accurately, continuously remodeling tissue, with old bone being absorbed and new bone being deposited in an ongoing balance that the body calibrates to the mechanical loads the bones are currently being asked to bear.
The calibration depends, in some real way, on the loads being there in the first place. When the loads disappear, the calibration changes. The body, by structural design, does not waste resources maintaining bone density that no longer appears to be needed. The bone density is, accordingly, reduced. The reduction continues for as long as the unloading continues.
The most dramatic available demonstration of this is what happens to astronauts on the International Space Station. In microgravity, the weight-bearing bones of the lower body are no longer being asked to bear weight. The body, registering the absence of load, reduces the bone density of these regions at a rate that, by every available terrestrial comparison, is alarming.
The specific rate, and what it compares to
The standard figure for astronaut bone loss has been documented across decades of spaceflight research. Research published in the wider scientific literature documents that in early human spaceflight missions, the weight-bearing bones of astronauts lost between 1 and 2 percent of their bone mineral density per month. The figure applies specifically to the bones that, on Earth, are doing the structural work of supporting the body against gravity. These include the lower vertebrae, the pelvis, the femur, the tibia, and the fibula. The bones of the upper body, which on Earth do less weight-bearing work, lose density more slowly.
The 1 to 2 percent per month figure is, on close examination, considerably worse than it sounds in isolation. A postmenopausal woman, who is by every standard medical measurement at significant risk for osteoporosis, loses bone density at approximately 1 to 2 percent per year. An astronaut on a six-month ISS mission, accordingly, loses approximately the same amount of bone mass in six months that a postmenopausal woman loses across a full year. A typical six-month spaceflight produces, in the weight-bearing bones, a level of demineralization that would, on Earth, be considered a serious medical concern requiring active intervention.
The implications for long-duration spaceflight are, on the available evidence, considerable. A Mars mission, which by current planning would involve approximately 30 months of microgravity exposure, could in principle produce bone loss in the range of 30 to 60 percent of original density if no countermeasures were applied. The 30 to 60 percent figure is, by every available terrestrial comparison, structurally catastrophic. The bones would not, in most cases, be able to support normal use even after return to Earth.
What NASA developed to slow the loss
The countermeasures NASA has developed to address this problem are, on close examination, considerably more substantial than the standard cultural framing tends to credit. The countermeasures involve a combination of resistance exercise, aerobic exercise, and in some cases pharmaceutical intervention, all of which are deployed continuously across the duration of any extended ISS mission.
The centerpiece of the exercise countermeasures is the Advanced Resistive Exercise Device, or ARED, which was installed on the ISS in 2008. The ARED uses vacuum cylinders to simulate the resistance of free weights, allowing astronauts to perform squats, deadlifts, bench presses, and other resistance exercises that, on Earth, would require gravity-loaded free weights to perform. The astronauts use the ARED for approximately two hours per day, in combination with treadmill and cycling exercises calibrated to maintain cardiovascular fitness.
The exercise countermeasures are sometimes combined with pharmaceutical intervention. Research on the ISS has documented that astronauts who take the anti-resorptive drug alendronate, beginning three weeks before launch and continuing throughout the mission, show partial inhibition of the expected bone loss when the drug is combined with resistive exercise on the ARED. The combined approach produces, on the available evidence, the best currently documented outcomes for preserving bone density across extended missions.
The effectiveness of these countermeasures is, on close examination, partial rather than complete. The astronauts still lose bone density. The loss is, however, considerably smaller than the loss in the pre-countermeasure era. The countermeasures have, in some real way, brought astronaut bone loss into a manageable range for missions of six months or less. For longer missions, the existing countermeasures are not, on the available evidence, currently sufficient.
What happens after the astronauts return
The recovery side of the equation is, on close examination, more sobering than the standard cultural framing tends to allow for. Research published in Scientific Reports followed astronauts for twelve months after their return from long-duration spaceflight, measuring the recovery of bone strength and trabecular bone microarchitecture at the distal tibia. The findings were unambiguous. Twelve months after flight, the astronauts’ bone strength, total bone mineral density, cortical and trabecular bone density, and trabecular bone volume fraction remained 0.9 to 2.1 percent below pre-flight values. Astronauts on longer missions, longer than six months, had poorer recovery than astronauts on shorter missions.
The implications of this for the wider question of how bone responds to extended unloading are considerable. Microgravity appears to produce, in at least some astronauts, irreversible damage to bone density and trabecular microarchitecture. The damage is partially recoverable but not, on the available evidence, fully recoverable, even with the existing countermeasures. The sustained losses represent, by the researchers’ own calculation, approximately a decade of normal age-related bone loss. The astronauts are, in some real way, returning from their missions structurally aged by a decade in terms of their skeletal health.
What the terrestrial implications are
The structural similarity between microgravity-induced bone loss and the bone loss that occurs in osteoporosis, particularly disuse osteoporosis associated with prolonged bed rest, has been recognized for several decades. The astronauts’ bones, in microgravity, are doing something structurally similar to what the bones of bedridden or immobilized elderly patients are doing on Earth. The mechanism in both cases involves reduced mechanical loading, which triggers the body’s calibration toward reduced bone density in the affected regions.
This similarity is what has driven the wider research interest in adapting astronaut countermeasures for terrestrial osteoporosis treatment. The ARED-style resistance exercise protocols, developed for ISS astronauts, are now being studied in terrestrial clinical contexts. The drug protocols combining resistance exercise with bisphosphonates, refined through ISS research, have been informing the development of similar protocols for postmenopausal women and elderly patients with osteoporosis. The mechanical loading research, particularly the research on low-magnitude, high-frequency mechanical stimulation, has produced findings that are being explored as potential treatments for bone loss in populations who have never left the ground.
The transfer is not, on close examination, complete. Microgravity bone loss and terrestrial osteoporosis are similar but not identical. The microgravity case involves rapid loss in otherwise healthy young adults. The terrestrial case usually involves slower loss in older adults whose bone biology has additional age-related complications. The countermeasures that work in the microgravity case do not, in all cases, directly transfer to the terrestrial case. The transfer requires careful clinical adaptation.
What has transferred most readily, on the available evidence, is the basic framework. The ISS research has established, with considerably more precision than any previous research had managed, that mechanical loading is, in some real way, the primary signal that the body uses to maintain bone density, and that the absence of mechanical loading produces structurally dramatic bone loss across surprisingly short time scales. The implications of this framework for the treatment of terrestrial disuse osteoporosis, hospitalization-related bone loss, and certain forms of age-related bone loss have been, across the last decade, increasingly visible in the clinical literature.
The acknowledgment this article wants to leave
Astronauts on the ISS lose approximately 1 to 2 percent of their bone density per month in microgravity, which is approximately equivalent in monthly terms to what a postmenopausal woman loses across an entire year. The bone loss is, on the available evidence, only partially recovered after return to Earth, and the partial recovery represents approximately a decade of accelerated skeletal aging. The countermeasures NASA has developed to slow the loss, including the Advanced Resistive Exercise Device and combined exercise-pharmaceutical protocols, are now being studied as potential treatments for terrestrial osteoporosis patients who have never left the ground.
The transfer of knowledge from microgravity research to terrestrial clinical practice is, in some real way, one of the more underappreciated benefits of the ISS as a research platform. The wider cultural register tends to think about the ISS in terms of its visible scientific achievements in astronomy, biology, and materials science. The contributions to terrestrial medicine, particularly in skeletal biology, have been less visible but on close examination considerably more directly applicable to the daily lives of the wider population than most of the more glamorous ISS research has been. The applicability is what most of the contemporary research on disuse-related bone loss is, in some real way, structurally building on.
